Exploring Thioredoxin-Interacting Protein (TXNIP) as a Therapeutic Target for Cardiovascular Diseases.

Cardiovascular diseases (CVDs) are the primary causes of death globally. Risk factors such as aging, poor lifestyle, and genetics significantly influence how these diseases progress, with oxidative stress being an important factor in their pathogenesis. Thioredoxin-interacting protein (TXNIP), a redox regulator, has emerged as a crucial mediator in oxidative stress-mediated CVD.

Targeting high-mobility-group-box-1-mediated inflammation: a promising therapeutic approach for myocardial infarction.

Myocardial ischemia, resulting from coronary artery blockage, precipitates cardiac arrhythmias, myocardial structural changes, and heart failure. The pathophysiology of MI is mainly based on inflammation and cell death, which are essential in aggravating myocardial ischemia and reperfusion injury. Emerging research highlights the functionality of high mobility group box-1, a non-histone nucleoprotein functioning as a chromosomal stabilizer and inflammatory mediator.